The secondary prevention of coronary artery disease

American Journal of Medicine

Volumn 102, Issue 6, 1997, Pages 572-581

  Bairey Merz, C Noel ^c   Rozanski, Alan ^a,b   Forrester, James S ^d  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Columbia Sch of Phys and Surgs ^*  (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOFIBRATE; COLESTYRAMINE; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

CORONARY ARTERY DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; LOW FAT DIET; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; SMOKING CESSATION; STRESS; WEIGHT REDUCTION;

CORONARY DISEASE; DIABETES MELLITUS; EXERCISE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SMOKING CESSATION; STRESS, PSYCHOLOGICAL; WEIGHT LOSS;

EID: 0343196712     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00046-6     Document Type: Review

References (140)

1. Sullivan LW. Healthy people 2000. NEJM. 1990;323:1065-1067.
2. Leaf A, Ryan TJ. Prevention of coronary artery disease. A medical imperative. NEJM. 1990;323:1416-1419.
3. Harrison DC. Cost containment in medicine: why cardiology? Am J Cardiol. 1981;56:10-15C.
4. American Heart Association. 1995 Heart and Stroke Facts. Dallas, Texas: American Heart Association; 1995.
5. Peduzzi P, Detre K, Murphy ML, et al. Ten-year incidence of myocardial infarction and prognosis after infarction: Department of Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery. Circulation. 1991;83:747-755.
6. Weintaub WS, Ghazzal ZMB, Cohen CL, et al. Clinical implications of late proven patency after successful coronary angioplasty. Circulation. 1991;84: 572-582.
7. Rogers WJ, Coggin CJ, Gersh BJ, et al. Ten-year follow-up of quality of life in patients randomized to receive medical therapy or coronary artery bypass graft surgery. Circulation. 1990;82:1647-1658.
8. Holmes DR, Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation. 1986; 73:1254-1263.
9. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
10. Research Committee of the Scottish Society of Physicians, lschaemia Heart Disease: A secondary prevention trial using clofibrate. BMJ. 1971;4:775-784.
11. Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. Lancet. 1968;2:693-700.
12. Carlson LA, Danielson M, Ekberg I, et al. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis. 1977;28:81-86.
13. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
14. Detre KM, Shaw L. Long-term changes of serum cholesterol with cholesterol-altering drugs in patients with coronary heart disease. Circulation. 1974; 50:998-1005.
15. Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral vascular disease. Atnerosclerosis. 1972;15:177-183.
16. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of chronic heart disease. BMJ. 1971;4:767-775.
17. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344:1383-1389.
18. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM. 1996;335:1001-1009.
19. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. Br Heart J. 1993;69(suppl):S42-S47.
20. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study (4S). Lancet 1995;345:1274-1275.
21. Stewart BF, Brown BG, Zhao Z-Q, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol. 1994;23:899-906.
22. Kuo PT, Hayase K, Kostic JB, Moreyra AE. Use of combined diet and colestipol in long-term (7-7.5 years) treatment of patients with type II hyperlipoproteinemia. Circulation. 1979;59:199-214.
23. Nash DT, Gensini G, Esente P. Effect of lipid lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography. Int J Cardiol. 1982;2:43-55.
24. Nikkila EA, Vilkinkoski P, Valle M, Frick MH. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidemia: A seven-year prospective angiographic study. BMJ. 1984;289:220-223.
25. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. NEJM. 1990;323:1289-1298.
26. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. NEJM. 1990;323:946-955.
27. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
28. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
29. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.
30. Cashin-Hemphill L, Mack MJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA. 1990;264:3013-3017.
31. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
32. Schuler G, Hambrecht R, Schlierf G, et al. Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet. J Am Coll Cardiol. 1992;19:34-42.
33. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013-3017.
34. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med. 1993;119: 969-976.
35. Stone PH, Gibson CM, Pasternak RC, et al. Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression. The Harvard Atherosclerosis Reversibility Project Study Group. Am J Cardiol. 1993;71:766-772.
36. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
37. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
38. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
39. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
40. Ball KP, Hanington E, McAllen PM, et al. Low fat diet in myocardial infarction. Lancet. 1965;2:501-504.
41. Leren P. The Oslo diet heart study. Eleven year report. Circulation. 1970;40:935-942.
42. Rose GA, Thompson WB, Williams RT. Corn oil in treatment of ischemic heart disease. BMJ. 1965;1:1531-1533.
43. Woodhill JM, Palmer AJ, Leelarthaepin B, et al. Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Advances in Exper Med Biology. 1978;109:317-330.
44. Singh RB, Rastogi SS, Verma R, et al. Randomized controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ. 1992;304:1015-1019.
45. Burr ML, Gilbert JG, Holliday RM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757-761.
46. Lorgeril M, Renaud S, Nicole M, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994; 343:1454-1459.
47. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Gene expression in macrophage-rich human atherosclerotic lesions. 15 Lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest. 1991;87:1146-1152.
48. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
49. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808-1811.
50. Ulbricht TLV, Southgate DAT. Coronary heart disease: seven dietary factors. Lancet. 1991;338:985-992.
51. Kentala E. Physical fitness and feasibility of physical rehabilitation after myocardial infarction in men of working age. Ann Clin Res. 1972;4(suppl 9): 1-8.
52. Sanne H. Exercise tolerance and physical training of nonselected patients after myocardial infarction. Acta Med Scand. 1973;(suppl 551):1-124.
53. Wilhemsen L, Sanne H, Elmfeldt D, et al. A controlled trial of physical training after myocardial infarction. Effects on risk factors, nonfatal reinfarction, and death. Prev Med. 1975;4:491-508.
54. Kallio V. Results of rehabilitation in coronary patients. Adv Cardiol. 1978; 24:153-163.
55. Kallio V, Hamalainen H, Hakkila J, Luurila OJ. Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. Lancet. 1979;2:1091-1094.
56. Carson P, Phillips R, Lloyd M, et al. Exercise after myocardial infarction: a controlled trial. JR Coll Physicians Lond. 1982;16:147-151.
57. Vermeulen A, Lie KI, Durrer D. Effects of cardiac rehabilitation after myocardial infarction: changes in coronary risk factors and long-term prognosis. Am Heart J. 1983;105:798-801.
58. Shaw LW. Effects of a prescribed supervised exercise program on mortality and cardiovascular morbidity in patients after a myocardial infarction. The National Exercise and Heart Disease Project. Am J Cardiol. 1981;48:39-46.
59. Rechnitzer P, Cunningham DA, Andrew GM, et al. Relation of exercise to the recurrence rate of myocardial infarction in men. Ontario Exercise - Heart Collaborative Study. Am J Cardiol. 1983;51:65-69.
60. Lamm G, Denolin H, Dorossiev D, Pisa Z. Rehabilitation and secondary prevention of patients after acute myocardial infarction: WHO Collaborative Study. Cardiol. 1982;31:107-111.
61. Marra S, Paolillo V, Spadaccini F, Angelino PF. Long-term follow-up after a controlled randomized post-myocardial infarction rehabilitation programme: effects on morbidity and mortality. Eur Heart J. 1985;6:656-663.
62. Hare DL, Worcester M, Goble AJ. The effects of early exercise training on outcome one year after myocardial infarction. The Cardiac Society of Australia and New Zealand, August 1983;412-413. Abstract.
63. Bethel HJN. Rehabilitation of coronary patients. Practitioner. 1982;226: 477-482.
64. Froelicher V, Jensen D, Genter F, et al. A randomized trial of exercise training patients with coronary heart disease. JAMA. 1984;252:1291-1297.
65. Miller MH, Haskell WL, Berra K, DeBusk RF. Home versus group exercise training for increasing functional capacity after myocardial infarction. Circulation. 1984;70:645-649.
66. Roman O, Gutierrez M, Luksie I, et al. Cardiac rehabilitation after myocardial infarction: nine-year controlled follow-up study. Cardiology. 1983;70: 223-231.
67. World Health Organization. Rehabilitation and comprehensive secondary prevention after acute myocardial infarction. EURO Rep Study. 1983;84:1-99.
68. Palatsi I. Feasibility of physical training after myocardial infarction and its effect on return to work, morbidity, and mortality. Acta Med Scand. 1976;559:1-84.
69. Mayou R, MacMahon D, Sleight P, et al. Early rehabilitation after myocardial infarction. Lancet. 191;2:1399-1401.
70. Hedback B, Perk J. Five-year results of a comprehensive rehabilitation programme after myocardial infarction. Eur Heart J. 1987;8:234-242.
71. Stern MJ, Cleary P. National Exercise and Heart Disease Project: psychosocial changes observed during a low-level exercise program. Arch Intern Med. 1981;141:1463-1467.
72. Stern MJ, Cleary P. The National Exercise and Heart Disease Project: long-term psychosocial outcome. Arch Intern Med. 1982;142:1093-1097.
73. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation. 1989; 80:234-244.
74. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA. 1988;260:945-950.
75. Nolewajka AJ, Kostuk WJ, Rechnitzer PA, et al. Exercise and human collateralization: an angiographic and scintigraphic assessment. Circulation. 1979;60:114-122.
76. Verani MS, Hartung GH, Harris-Hoepfel J, et al. Effects of exercise training on left ventricular performance and myocardial perfusion in patients with coronary artery disease. Am J Cardiol. 1981;47:797-803.
77. Hung J, Gordon EP, Houston N, et al. Changes in rest and exercise myocardial perfusion and left ventricular function 3 to 26 weeks after clinically uncomplicated acute myocardial infarction: Effects of exercise training. Am J Cardiol. 1984;54:943-950.
78. Sebrechts CP, Klein JL, Ahnve S, et al. Myocardial perfusion changes following 1 year of exercise training assessed by thallium-201 circumferential count profiles. Am Heart J. 1986;112:1217-1226.
79. Schuler G, Schlierf G, Wirth A, et al. Low-fat diet and regular, supervised physical exercise in patients with symptomatic coronary artery disease: reduction of stress-induced myocardial ischemia. Circulation. 1988;77:172-181.
80. Todd IG, Bradnam MS, Cooke MBD, Ballantyne D. Effects of daily high-intensity exercise on myocardial perfusion in angina pectoris. Am J Cardiol. 1991;68:1593-1599.
81. Gould KL, Martucci JP, Goldberg Dl, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89:1530-1538.
82. Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA. 1995;274:894-901.
83. Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. J Am Coll Cardiol. 1986;7:464-471.
84. Gibson RS, Watson DD, Craddock GB, et al. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation. 1983;68:321-336.
85. Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardiol. 1991;67:1084-1089.
86. Dracup K, Moser DK, Marsden C, et al. Effects of a multidimensional cardiopulmonary rehabilitation program on psychosocial function. Am J Cardiol. 1991;68:31-34.
87. Perk J, Hedback B, Engvall J. Effects of cardiac rehabilitation after coronary artery bypass grafting on readmissions, return to work and physical fitness. Scand J Soc Med. 1990;18:45-51.
88. Butler J, O'Brien M, O'Malley K, et al. Relationship of beta-adrenoreceptor density to fitness in athletes. Nature. 1982;298:60-62.
89. Bairey CN. Exercise and coronary artery disease - what should we be recommending to our patients (and ourselves). West Med. 1986;144:205-211.
90. Gould KL, Ornish D, Kirkeeide R, et al. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. Am J Cardiol. 1992;69:845-853.
91. Rose GA, Hamilton PJS, Colwell L, Shipley MJ. A randomized controlled trial of antismoking advice: 10 year results. J Epidem Comm Health. 1982; 36:102-108.
92. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA. 1982;248: 1465-1477.
93. Hjermann I, Holme I, Byre KV, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet. 1981;2: 1303-1310.
94. Wilhemsson C, Elmfeldt D, Vedin JA, Tibblin G. Smoking and myocardial infarction. Lancet. 1975;1:415-419.
95. Winniford MD, Jansen DE, Reynolds GA, et al. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol. 1987;59:203-207.
96. Davis JW, Hartman CR, Lewis HD Jr, et al. Cigarette smoking-induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med. 1985;105:479-483.
97. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 1986;113:1006-1010.
98. Taylor AE, Johnson DC, Kazemi H. Environmental tobacco smoke and cardiovascular disease. A position paper from the Council on Cardiopulmonary and Critical Care, American Heart Association. Circulation. 1992;86:699-702.
99. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485-489.
100. Amery A, Brixxo P, Clement D, et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet. 1985;1:1349-1370.
101. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974;229:401-418.
102. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
103. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
104. The Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267:1213-1220.
105. Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure: Final report of a four-year randomized controlled trial - the hypertension control program. JAMA. 1987;257:1484-1491.
106. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
107. Sutton-Tyrrell K, Alcorn HG, Herzog H, et al. Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke. 1995;26:1319-1324.
108. Curb JD, Maxwell MH, Schneider KA, et al. Adverse effects of antihypertensive medications in the hypertension detection and follow-up program. Prog Cardiovasc Dis. 1986;29(suppl 1):73-88.
109. Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med. 1995; 123:481-479.
110. Shuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects of progression on coronary artery disease. Circulation. 1992;86:1-11.
111. Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight reducing diet, with or without exercise, in overweight men and women. NEJM. 1991;325:461-466.
112. Denke MA. Cholesterol-lowering diets. A review of the evidence. Arch Intern Med. 1995;155:17-26.
113. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol. 1995; 75:894-903.
114. Adsett CA, Bruhn JG. Short-term group psychotherapy for post-myocardial patients and their wives. Can Med Assoc J. 1968;99:577.
115. Ibrahim MA, Feldman JG, Sultz HA, et al. Management after myocardial infarction: a controlled trial of the effect of group psychotherapy. Int J Psychiatry Med. 1974;5:253-268.
116. Rahe RH, Ward HW, Hayes V. Brief group therapy in myocardial infarction rehabilitation: three to four year follow-up of a controlled trial. Psychosom Med. 1979;41:229-242.
117. Frasure-Smith N, Prince R. The ischemic heart disease life stress monitoring program: impact on mortality. Psycnosom Med. 1985;47:431-445.
118. Fielding R. A note on behavioral treatment in the rehabilitation of myocardial infarction patients. Br J Soc Clin Psychol. 1980;19:157-161.
119. Salonea JT, Pusha P. A community for rehabilitation and secondary prevention for patients with acute myocardial infarction as part of a comprehensive community programme for control of cardiovascular diseases (North Karelia Project). Scand J Rehabil Med. 1980;12:33-41.
120. Gruen W. Effects of brief psychotherapy during the hospitalization period on the recovery process in heart attacks. J Consult Clin Psychol. 1975;43:223-232.
121. Ornish D, Scherwitz LW, Doody RS, et al. Effects of stress management training and dietary changes in treating heart disease. JAMA. 1983;249:54-59.
122. Friedman M, Thoresen CE, Gill JJ, et al. Alteration of Type A behavior and reduction in cardiac recurrences in postmyocardial infarction patients. Am Heart J. 1984;108:237-248.
123. Jenni MA, Wollersheim JP. Cognitive therapy, stress management training, and the Type A behavior pattern. Cognit Ther Res. 1979;3:61-73.
124. Wallace N, Wallace DC. Group education after myocardial infarction: is it effective? Med J Aust. 1977;20:245-247.
125. Tulpule TH, Tulpule AT. Yoga, a method of relaxation for rehabilitation after myocardial infarction. Ind Heart J. 1980;32:1-7.
126. Stern MJ, Gorman PA, Kaslow L. The group counseling vs. exercise therapy study a controlled intervention with subjects following myocardial infarction. Arch Intern Med. 1983;143:1719-1725.
127. Nunes EV, Frank KA, Kornfeld DS. Psychologic treatment for type A behavior pattern and for coronary artery disease: a meta-analysis of the literature. Psychom Med. 1987;49:159-173.
128. Frasure-Smith N, Prince R. Long-term follow-up of the Ischemic Heart Disease Life Stress Monitoring Program. Psychosom Med. 1984;51:485-513.
129. Kaplan JR, Manuck SB, Clarkson TB, et al. Social status, environment, and atherosclerosis in cynomologous monkeys. Arteriosclerosis. 1982;2:359-368.
130. Rozanski AR, Bairey CN, Krantz DS, et al. Mental stress and silent myocardial ischemia in coronary artery disease patients. NEJM. 1988;318:1005-1012.
131. Follick MJ, Gorkin L, Capone RJ, et al. Psychological distress as a predictor of ventricular arrhythmias in a post-myocardial infarction population. Am Heart J. 1988;116:32-36.
132. Krantz DS, Helmers KF, Bairey CN, et al. Psychophysiologic reactivity and determinants of myocardial oxygen demand in mental stress induced myocardial ischemia. Psychosomatic Med. 1990;53:1-12.
133. Yeung A, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. NEJM. 1991;325:1551-1556.
134. Levine SP, Towell BL, Surarez AM, et al. Platelet activation and secretion associated with emotional stress. Circulation. 1985;71:1129-1134.
135. Verrier RL. Mechanisms of behaviorally induced arrhythmias. Circulation. 1987;76(suppl 1):148-156.
136. Antiplatelet Trialist's Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1983;296:320-331.
137. The Beta-Blocker Pooling Project Research Group. The Beta-Blockers Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. European Heart J. 1988;9:8-16.
138. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;334:563-570.
139. Smith SC, Blair SN, Criqui MH, et al. American Heart Association Consensus Panel Statement: Preventing Heart Attack and Death in Patients with Coronary Disease. Circulation. 1995;26:2912-2914.
140. Forrester JS, Bairey Merz CN, Bush TL, et al. Task Force 4. Efficacy of Risk Factor Management, from the 27th Bethesda Conference. J Am Coll Cardiol. 1996;27:991-1006.